Association of Asn221Ser mutation in tissue factor pathway inhibitor-β with plasma total tissue factor pathway inhibitor level

Junko Ishikawa, Hiromi Okada, Hisao Kato, Satoshi Takeshita, Shigenori Honda, Tomio Kawasaki, Etsuji Suehisa, Hajime Tsuji, Seiji Madoiwa, Yoichi Sakata, Tetsuhito Kojima, Mitsuru Murata, Yasuo Ikeda, Yoshihiro Kokubo, Tomonori Okamura, Hitonobu Tomoike, Toshiyuki Miyata

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Tissue factor pathway inhibitor (TFPI) is an anticoagulant protease inhibitor that inhibits the tissue factor-initiated blood coagulation cascade reactions. Based on these anticoagulant functions of TFPI, we hypothesized that genetic variations in TFPI may alter the TFPI expression or impair the anticoagulant function and could predispose persons to deep vein thrombosis (DVT). This study was undertaken to examine whether the genetic polymorphisms in TFPI are associated with the plasma TFPI levels and risk for DVT. We sequenced the entire coding regions of TFPI in 175 Japanese DVT patients and identified 12 genetic variants, including one missense mutation, Asn221Ser. The missense mutation occurred at the site presumably attached to the glycosylphosphatidylinositol anchor in the TFPI-p form. The allele frequency of the mutant Ser-coding allele of the Asn221Ser mutation was 8% in the Japanese general population consisting of 1684 individuals. The Asn221Ser mutation was significantly associated with the total TFPI levels (Asn/Asn, n = 108, total TFPI = 56.57 ± 0.88 ng/ml (mean ± SD) vs. Asn/Ser + Ser/Ser, n = 16, total TFPI = 63.44 ±.28 ng/ml, P= 0.0058). The genotype was not associated with the free TFPI level. This Asn221Ser mutation was not associated with DVT. Thus, the Asn221Ser mutation occurring in the TFPI-p form was associated with the total TFPI level, but not a risk for DVT. The absence of the putative glycosylphosphatidylinositol anchor in TFPI-β under pathological conditions remains to be studied. Blood Coagul Fibrinolysis 20:22-26

Original languageEnglish
Pages (from-to)22-26
Number of pages5
JournalBlood Coagulation and Fibrinolysis
Volume20
Issue number1
DOIs
Publication statusPublished - 2009 Jan

Fingerprint

Mutation
Venous Thrombosis
Anticoagulants
Glycosylphosphatidylinositols
lipoprotein-associated coagulation inhibitor
Missense Mutation
Thromboplastin
Blood Coagulation
Fibrinolysis
Genetic Polymorphisms
Protease Inhibitors
Gene Frequency
Alleles
Genotype

Keywords

  • Deep vein thrombosis
  • Glycosylphosphatidylinositol
  • Tissue factor pathway inhibitor

ASJC Scopus subject areas

  • Hematology

Cite this

Association of Asn221Ser mutation in tissue factor pathway inhibitor-β with plasma total tissue factor pathway inhibitor level. / Ishikawa, Junko; Okada, Hiromi; Kato, Hisao; Takeshita, Satoshi; Honda, Shigenori; Kawasaki, Tomio; Suehisa, Etsuji; Tsuji, Hajime; Madoiwa, Seiji; Sakata, Yoichi; Kojima, Tetsuhito; Murata, Mitsuru; Ikeda, Yasuo; Kokubo, Yoshihiro; Okamura, Tomonori; Tomoike, Hitonobu; Miyata, Toshiyuki.

In: Blood Coagulation and Fibrinolysis, Vol. 20, No. 1, 01.2009, p. 22-26.

Research output: Contribution to journalArticle

Ishikawa, J, Okada, H, Kato, H, Takeshita, S, Honda, S, Kawasaki, T, Suehisa, E, Tsuji, H, Madoiwa, S, Sakata, Y, Kojima, T, Murata, M, Ikeda, Y, Kokubo, Y, Okamura, T, Tomoike, H & Miyata, T 2009, 'Association of Asn221Ser mutation in tissue factor pathway inhibitor-β with plasma total tissue factor pathway inhibitor level', Blood Coagulation and Fibrinolysis, vol. 20, no. 1, pp. 22-26. https://doi.org/10.1097/MBC.0b013e328304e0b9
Ishikawa, Junko ; Okada, Hiromi ; Kato, Hisao ; Takeshita, Satoshi ; Honda, Shigenori ; Kawasaki, Tomio ; Suehisa, Etsuji ; Tsuji, Hajime ; Madoiwa, Seiji ; Sakata, Yoichi ; Kojima, Tetsuhito ; Murata, Mitsuru ; Ikeda, Yasuo ; Kokubo, Yoshihiro ; Okamura, Tomonori ; Tomoike, Hitonobu ; Miyata, Toshiyuki. / Association of Asn221Ser mutation in tissue factor pathway inhibitor-β with plasma total tissue factor pathway inhibitor level. In: Blood Coagulation and Fibrinolysis. 2009 ; Vol. 20, No. 1. pp. 22-26.
@article{e44082e9fe6344d78306b7e3f50a886b,
title = "Association of Asn221Ser mutation in tissue factor pathway inhibitor-β with plasma total tissue factor pathway inhibitor level",
abstract = "Tissue factor pathway inhibitor (TFPI) is an anticoagulant protease inhibitor that inhibits the tissue factor-initiated blood coagulation cascade reactions. Based on these anticoagulant functions of TFPI, we hypothesized that genetic variations in TFPI may alter the TFPI expression or impair the anticoagulant function and could predispose persons to deep vein thrombosis (DVT). This study was undertaken to examine whether the genetic polymorphisms in TFPI are associated with the plasma TFPI levels and risk for DVT. We sequenced the entire coding regions of TFPI in 175 Japanese DVT patients and identified 12 genetic variants, including one missense mutation, Asn221Ser. The missense mutation occurred at the site presumably attached to the glycosylphosphatidylinositol anchor in the TFPI-p form. The allele frequency of the mutant Ser-coding allele of the Asn221Ser mutation was 8{\%} in the Japanese general population consisting of 1684 individuals. The Asn221Ser mutation was significantly associated with the total TFPI levels (Asn/Asn, n = 108, total TFPI = 56.57 ± 0.88 ng/ml (mean ± SD) vs. Asn/Ser + Ser/Ser, n = 16, total TFPI = 63.44 ±.28 ng/ml, P= 0.0058). The genotype was not associated with the free TFPI level. This Asn221Ser mutation was not associated with DVT. Thus, the Asn221Ser mutation occurring in the TFPI-p form was associated with the total TFPI level, but not a risk for DVT. The absence of the putative glycosylphosphatidylinositol anchor in TFPI-β under pathological conditions remains to be studied. Blood Coagul Fibrinolysis 20:22-26",
keywords = "Deep vein thrombosis, Glycosylphosphatidylinositol, Tissue factor pathway inhibitor",
author = "Junko Ishikawa and Hiromi Okada and Hisao Kato and Satoshi Takeshita and Shigenori Honda and Tomio Kawasaki and Etsuji Suehisa and Hajime Tsuji and Seiji Madoiwa and Yoichi Sakata and Tetsuhito Kojima and Mitsuru Murata and Yasuo Ikeda and Yoshihiro Kokubo and Tomonori Okamura and Hitonobu Tomoike and Toshiyuki Miyata",
year = "2009",
month = "1",
doi = "10.1097/MBC.0b013e328304e0b9",
language = "English",
volume = "20",
pages = "22--26",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Association of Asn221Ser mutation in tissue factor pathway inhibitor-β with plasma total tissue factor pathway inhibitor level

AU - Ishikawa, Junko

AU - Okada, Hiromi

AU - Kato, Hisao

AU - Takeshita, Satoshi

AU - Honda, Shigenori

AU - Kawasaki, Tomio

AU - Suehisa, Etsuji

AU - Tsuji, Hajime

AU - Madoiwa, Seiji

AU - Sakata, Yoichi

AU - Kojima, Tetsuhito

AU - Murata, Mitsuru

AU - Ikeda, Yasuo

AU - Kokubo, Yoshihiro

AU - Okamura, Tomonori

AU - Tomoike, Hitonobu

AU - Miyata, Toshiyuki

PY - 2009/1

Y1 - 2009/1

N2 - Tissue factor pathway inhibitor (TFPI) is an anticoagulant protease inhibitor that inhibits the tissue factor-initiated blood coagulation cascade reactions. Based on these anticoagulant functions of TFPI, we hypothesized that genetic variations in TFPI may alter the TFPI expression or impair the anticoagulant function and could predispose persons to deep vein thrombosis (DVT). This study was undertaken to examine whether the genetic polymorphisms in TFPI are associated with the plasma TFPI levels and risk for DVT. We sequenced the entire coding regions of TFPI in 175 Japanese DVT patients and identified 12 genetic variants, including one missense mutation, Asn221Ser. The missense mutation occurred at the site presumably attached to the glycosylphosphatidylinositol anchor in the TFPI-p form. The allele frequency of the mutant Ser-coding allele of the Asn221Ser mutation was 8% in the Japanese general population consisting of 1684 individuals. The Asn221Ser mutation was significantly associated with the total TFPI levels (Asn/Asn, n = 108, total TFPI = 56.57 ± 0.88 ng/ml (mean ± SD) vs. Asn/Ser + Ser/Ser, n = 16, total TFPI = 63.44 ±.28 ng/ml, P= 0.0058). The genotype was not associated with the free TFPI level. This Asn221Ser mutation was not associated with DVT. Thus, the Asn221Ser mutation occurring in the TFPI-p form was associated with the total TFPI level, but not a risk for DVT. The absence of the putative glycosylphosphatidylinositol anchor in TFPI-β under pathological conditions remains to be studied. Blood Coagul Fibrinolysis 20:22-26

AB - Tissue factor pathway inhibitor (TFPI) is an anticoagulant protease inhibitor that inhibits the tissue factor-initiated blood coagulation cascade reactions. Based on these anticoagulant functions of TFPI, we hypothesized that genetic variations in TFPI may alter the TFPI expression or impair the anticoagulant function and could predispose persons to deep vein thrombosis (DVT). This study was undertaken to examine whether the genetic polymorphisms in TFPI are associated with the plasma TFPI levels and risk for DVT. We sequenced the entire coding regions of TFPI in 175 Japanese DVT patients and identified 12 genetic variants, including one missense mutation, Asn221Ser. The missense mutation occurred at the site presumably attached to the glycosylphosphatidylinositol anchor in the TFPI-p form. The allele frequency of the mutant Ser-coding allele of the Asn221Ser mutation was 8% in the Japanese general population consisting of 1684 individuals. The Asn221Ser mutation was significantly associated with the total TFPI levels (Asn/Asn, n = 108, total TFPI = 56.57 ± 0.88 ng/ml (mean ± SD) vs. Asn/Ser + Ser/Ser, n = 16, total TFPI = 63.44 ±.28 ng/ml, P= 0.0058). The genotype was not associated with the free TFPI level. This Asn221Ser mutation was not associated with DVT. Thus, the Asn221Ser mutation occurring in the TFPI-p form was associated with the total TFPI level, but not a risk for DVT. The absence of the putative glycosylphosphatidylinositol anchor in TFPI-β under pathological conditions remains to be studied. Blood Coagul Fibrinolysis 20:22-26

KW - Deep vein thrombosis

KW - Glycosylphosphatidylinositol

KW - Tissue factor pathway inhibitor

UR - http://www.scopus.com/inward/record.url?scp=58849136588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849136588&partnerID=8YFLogxK

U2 - 10.1097/MBC.0b013e328304e0b9

DO - 10.1097/MBC.0b013e328304e0b9

M3 - Article

C2 - 20523161

AN - SCOPUS:58849136588

VL - 20

SP - 22

EP - 26

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 1

ER -